Inborn Metabolic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/  PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain injury.
CP is a group of disorders that affect a person s ability to move and maintain balance and posture. Many of the common symptoms of CP are similar to other neurotransmitter disorders, such as Aromatic L-amino Acid Decarboxylase (AADC) deficiency, resulting in potential misdiagnosis. The program, PTC Pinpoint Direct™-CP Spectrum, is an innovative, genetic testing program which includes expert genetic counseling at no charge for eligible patients. ....

United States , Kylie Okeefe , Jane Baj , Invitae Corporation , Therapeutics Inc , Aromaticl Amino Acid Decarboxylase , Kylieo Keefe , Senior Vice President , Global Commercial , Corporate Strategy , Genome Medical , Inborn Metabolic , More Information , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Ptc Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , கைலி ஓக்கீபே , ஜேன் பஜ் , சிகிச்சை இன்க் , மூத்தவர் துணை ப்ரெஸிடெஂட் , உலகளாவிய வணிகரீதியானது , பெருநிறுவன மூலோபாயம் , மரபணு மருத்துவ , மேலும் தகவல் ,